Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glycyl-L-alpha-amino-epsilon-pimelyl-D-alanine is a synthetic tripeptide composed of glycine, L-alpha-amino-epsilon-pimelic acid, and D-alanine. It is an experimental small molecule that mimics a fragment of the natural peptidoglycan precursor found in bacterial cell walls. This compound has been used primarily as a biochemical tool to study the substrate specificity and mechanism of penicillin-binding proteins (PBPs), particularly D-Ala-D-Ala carboxypeptidases involved in bacterial cell wall biosynthesis. It is not approved for clinical use and has no known therapeutic indications[1][2][3][4]. Its main application is in structural biology studies to elucidate enzyme-substrate interactions relevant to antibiotic action and resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycyl-l-alpha-amino-epsilon-pimelyl-d-alanine.